Vyrex Corporation (OTCBB:VYRX) announced that it is proceeding with its plans to use its antioxidant and prodrug technologies to develop radioprotective agents against nuclear/radiologic terrorism. The first such agent, GEN-VYX1-2004, has been synthesized, has undergone initial animal toxicity studies and found to be non-toxic.
